Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine

Figures & data

Table 1 Demographics for survey participants

Characteristic	Total N (%)	Currently in care, N (%)	Previously engaged, N (%)
Total	35	16	19
Age (years)
25–34	3 (9)	1 (6)	2 (11)
35–44	16 (46)	9 (56)	8 (42)
45–54	11 (31)	4 (25)	6 (32)
55–64	4 (11)	1 (6)	3 (16)
65+	1 (3)	1 (6)	0 (0)
Gender
Male	23 (66)	12 (75)	11 (58)
Female	11 (31)	3 (19)	8 (42)
Trans	1 (3)	1 (6)	0 (0)
Economic status
Income solely from work	12 (34)	0 (0)	12 (63)
Income from work and welfare payments	6 (17)	4 (25)	2 (11)
Income from welfare payments	15 (43)	11 (69)	4 (21)
Other income source	2 (6)	1 (6)	1 (5)
Accommodation
Own a property	5 (14)	1 (6)	4 (21)
Live with friend(s) or family	3 (9)	1 (6)	2 (11)
Rent a property or part of	17 (49)	5 (31)	12 (63)
Temporary accommodation	6 (17)	6 (38)	0 (0)
Homeless	2 (6)	2 (13)	0 (0)
Other	2 (6)	1 (6)	1 (5)
Treatment status
Engagement in OUD treatment	–	16 (47)	19 (54)
Methadone	–	5 (31)	10 (53)
Buprenorphine	–	4 (25)	1 (5)
Buprenorphine/naloxone	–	2 (13)	0 (0)
Other therapy	–	2 (13)	8 (42)
No prescription	–	3 (19)	–
Pharmacy pick-up frequency
Daily	–	8 (50)	–
3 times per week	–	1 (6)	–
Weekly	–	4 (25)	–
Monthly	–	1 (6)	–
No medication	–	2 (13)	–

Abbreviation: OUD, opioid use disorder.

Figure 1 Service user view on current OUD treatment services.

Notes: People currently or previously engaged in OUD care services shared their views on experiences in treatment. Data denote percentage distribution of responses.
Abbreviation: OUD, opioid use disorder.

Figure 2 Service user view on potential future depot medications.

Notes: People currently or previously engaged in OUD care services shared their views on experiences in treatment. Data denote percentage distribution of responses.
Abbreviation: OUD, opioid use disorder.